Prasad Bollina

Medicine · Health Sciences

19h-index5.8kcitations47works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(27), Prostate Cancer Treatment and Research(23), Bladder and Urothelial Cancer Treatments(11), Urinary Bladder and Prostate Research(3), Inflammatory mediators and NSAID effects(3)

Publications45 total

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
New England Journal of Medicine·2023· 666 citedOpen Access
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment
NEJM Evidence·2023· 87 citedOpen Access
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment <scp>[ProtecT]</scp> study)
British Journal of Urology·2022· 82 citedOpen Access
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
BMC Cancer·2020· 14 citedOpen Access
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
BMJ Open·2020· 17 citedOpen Access
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
Health Technology Assessment·2020· 47 citedOpen Access
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
British Journal of Cancer·2020· 19 citedOpen Access
Erratum to ‘Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received’ [European Urology 77 (2020) 320–330]
European Urology·2020Open Access
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
European Urology·2019· 147 citedOpen Access
Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study
Journal of Clinical Epidemiology·2019· 9 citedOpen Access
Four‐year outcomes from a multiparametric magnetic resonance imaging (MRI)‐based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies
British Journal of Urology·2018· 49 citedOpen Access
MP73-13 DO FRAILER MEN BENEFIT FROM TURP?: A PROSPECTIVE AUDIT OF URO-FRAILTY MDT ASSESSMENT
The Journal of Urology·2018Open Access
Outcomes of frail and elderly patients undergoing TUR-P/BT in a single centre: The “Uro-Frailty MDT”
European Urology Supplements·2018
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
Journal of Clinical Epidemiology·2017· 20 citedOpen Access
What is the incidence of unsuspecting incidental prostate cancer in men undergoing transurethral resection of prostate?
International Journal of Surgery·2016Open Access
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
European Urology·2016· 44 citedOpen Access
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
New England Journal of Medicine·2016· 1.3k citedOpen Access
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
New England Journal of Medicine·2016· 2.6k citedOpen Access
Response to Editorial Comment “There's a Long Way to Go, But Now We Have a Map”
The Journal of Sexual Medicine·2016
Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance
Clinical Oncology·2016· 7 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Freddie C. Hamdy(17), Jenny Donovan(17), J. Athene Lane(17), David E. Neal(17), Alan Doherty(16), David Gillatt(16), Howard Kynaston(16), James W.F. Catto(15), Roger Kockelbergh(15), Alan Paul(15), Edward Rowe(15), Chris Metcalfe(14), T. J. Peters(14), Derek J. Rosario(14), Malcolm D. Mason(13), Emma L. Turner(13), Richard M. Martin(13), Vincent J. Gnanapragasam(13), Owen Hughes(13), Michael Davis(12)